Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Hao Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5141-2772; OpenAlex author ID A5100719808. Sources: OpenAlex.

Their work

Papers
17 (first author 2, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 17

  1. SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment. Co-author DOI 10.1002/mc.23936↗
  2. A novel nomogram and risk classification system based on inflammatory and immune indicators for predicting prognosis of pancreatic cancer patients with liver m… First author DOI 10.1002/cam4.6471↗
  3. Revealing platelet-related subtypes and prognostic signature in pancreatic adenocarcinoma. Last author DOI 10.1186/s12920-023-01530-x↗
  4. The Pre-Ablation Circulating Tumor-Associated Inflammatory Index Predicts the Prognosis of Patients with Liver Metastasis from Pancreatic Cancer. Last author DOI 10.2147/jir.s381807↗
  5. Multiple Perspectives Reveal the Role of DNA Damage Repair Genes in the Molecular Classification and Prognosis of Pancreatic Adenocarcinoma. Last author DOI 10.3390/ijms231810231↗
  6. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s12885-020-07023-9↗
  7. Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines. Co-author DOI 10.1016/j.bbrc.2019.02.092↗
  8. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Last author DOI 10.1186/s12967-019-1782-x↗
  9. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upreg… Co-author DOI 10.18632/aging.102307↗
  10. Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1848↗
  11. TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. Co-author DOI 10.1177/1534735418771193↗
  12. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. First author DOI 10.3233/cbm-170231↗
  13. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Co-author DOI 10.1002/cncr.30057↗
  14. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  15. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-3097-8↗
  16. Hyperfibrinogen Is Associated With the Systemic Inflammatory Response and Predicts Poor Prognosis in Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000353↗
  17. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0096177↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Linjia Peng · 4 shared papers, 2022–2023 · strength 0.98
  2. Zhen Chen · 12 shared papers, 2014–2020 · strength 0.90
  3. Lianyu Chen · 7 shared papers, 2014–2022 · strength 0.63
  4. Zhiqiang Meng · 9 shared papers, 2014–2019 · strength 0.62
  5. Yujie Li · 3 shared papers, 2022–2023 · strength 0.59
  6. Huifeng Gao · 2 shared papers, 2022 · strength 0.37
  7. Luming Liu · 5 shared papers, 2015–2019 · strength 0.37
  8. Ke Zhang · 2 shared papers, 2019–2023 · strength 0.31
  9. Yongqiang Hua · 4 shared papers, 2016–2019 · strength 0.30
  10. Peng Wang · 4 shared papers, 2014–2018 · strength 0.28
  11. Luming Liu · 4 shared papers, 2014–2019 · strength 0.25
  12. Ke Zhang · 2 shared papers, 2019–2020 · strength 0.22
  13. Jiangang Zhao · 1 shared paper, 2023 · strength 0.22
  14. Hui-Feng Gao · 2 shared papers, 2019–2020 · strength 0.22
  15. Yawen Geng · 3 shared papers, 2015–2018 · strength 0.20
  16. Zhe Cao · 1 shared paper, 2025 · strength 0.20
  17. Tao Liu · 1 shared paper, 2025 · strength 0.20
  18. Jianchun Xiao · 1 shared paper, 2025 · strength 0.20
  19. Jinxin Tao · 1 shared paper, 2025 · strength 0.20
  20. Yueze Liu · 1 shared paper, 2025 · strength 0.20
  21. Wenhao Luo · 1 shared paper, 2025 · strength 0.20
  22. Hua Huang · 1 shared paper, 2025 · strength 0.20
  23. Yifan Fu · 1 shared paper, 2025 · strength 0.20
  24. Yuanyang Wang · 1 shared paper, 2025 · strength 0.20
  25. Jun Wang · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.